JP5569710B2 - 肥満予防又は改善剤 - Google Patents
肥満予防又は改善剤 Download PDFInfo
- Publication number
- JP5569710B2 JP5569710B2 JP2009046388A JP2009046388A JP5569710B2 JP 5569710 B2 JP5569710 B2 JP 5569710B2 JP 2009046388 A JP2009046388 A JP 2009046388A JP 2009046388 A JP2009046388 A JP 2009046388A JP 5569710 B2 JP5569710 B2 JP 5569710B2
- Authority
- JP
- Japan
- Prior art keywords
- evaluation
- lactic acid
- technology
- national institute
- pediococcus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000008589 Obesity Diseases 0.000 title claims description 20
- 235000020824 obesity Nutrition 0.000 title claims description 20
- 230000003449 preventive effect Effects 0.000 title description 3
- 235000013305 food Nutrition 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 238000009825 accumulation Methods 0.000 claims description 15
- 238000011156 evaluation Methods 0.000 claims description 15
- 241000191996 Pediococcus pentosaceus Species 0.000 claims description 14
- 238000004113 cell culture Methods 0.000 claims description 9
- 230000006872 improvement Effects 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 70
- 239000004310 lactic acid Substances 0.000 description 35
- 235000014655 lactic acid Nutrition 0.000 description 35
- 241000894006 Bacteria Species 0.000 description 33
- 241000192001 Pediococcus Species 0.000 description 18
- 235000019197 fats Nutrition 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 230000037356 lipid metabolism Effects 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- 239000000284 extract Substances 0.000 description 13
- 230000009471 action Effects 0.000 description 8
- 208000004930 Fatty Liver Diseases 0.000 description 7
- 206010019708 Hepatic steatosis Diseases 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 208000010706 fatty liver disease Diseases 0.000 description 7
- 235000009200 high fat diet Nutrition 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 235000015140 cultured milk Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 210000001596 intra-abdominal fat Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 235000020083 shōchū Nutrition 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 4
- 210000000593 adipose tissue white Anatomy 0.000 description 4
- 230000023852 carbohydrate metabolic process Effects 0.000 description 4
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000021121 fermented vegetables Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 102000053028 CD36 Antigens Human genes 0.000 description 2
- 108010045374 CD36 Antigens Proteins 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 201000002451 Overnutrition Diseases 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- 235000014443 Pyrus communis Nutrition 0.000 description 2
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 2
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 2
- 241000500332 Tetragenococcus halophilus Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102100039066 Very low-density lipoprotein receptor Human genes 0.000 description 2
- 101710177612 Very low-density lipoprotein receptor Proteins 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000015190 carrot juice Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 235000020823 overnutrition Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000500353 Aerococcus urinaeequi Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000500340 Pediococcus damnosus Species 0.000 description 1
- 241000487050 Pediococcus pentosaceus ATCC 25745 Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021105 fermented cheese Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- SIARJEKBADXQJG-LFZQUHGESA-N stearoyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCCCCCCCCCCCCCCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 SIARJEKBADXQJG-LFZQUHGESA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Description
1)ペディオコッカス属(Pediococcus)に属する乳酸菌の菌体若しくは菌体培養物又はこれらの抽出物を有効成分とする肥満予防又は改善剤。
2)ペディオコッカス属(Pediococcus)に属する乳酸菌の菌体又はその培養物を有効成分とする脂肪蓄積抑制剤。
3)ペディオコッカス属(Pediococcus)に属する乳酸菌の菌体又はその培養物を有効成分とする脂質代謝改善剤。
4)ペディオコッカス属(Pediococcus)に属する乳酸菌の菌体若しくは菌体培養物又はこれらの抽出物を含有する肥満予防又は改善用食品。
5)ペディオコッカス属(Pediococcus)に属する乳酸菌が、独立行政法人製品評価技術基盤機構特許微生物寄託センターに、NITE AP−700として寄託されたペディオコッカス・ペントサセウス(Pediococcus pentosaceus) LP28株である1)の肥満予防若しくは改善剤、2)の脂肪蓄積抑制剤、3)の脂質代謝改善剤、又は4)の食品。
6)独立行政法人製品評価技術基盤機構特許微生物寄託センターに、NITE AP−700として寄託されたペディオコッカス・ペントサセウス(Pediococcus pentosaceus) LP28株。
ペディオコッカス属(Pediococcus)に属する乳酸菌としては、本発明の効果を示す限り特に限定されず、例えば、ペディオコッカス・ペントサセウス(Pediococcus pentosaceus)、ペディオコッカス・ダムノサス(Pediococcus damnosus)、ペディオコッカス・ウリナエッキー(Pediococcus urinaeequi)、ペディオコッカス・セレビシェ(Pediococcus cerevisiae)、ペディオコッカス・ハロフィルス(Pediococcus halophilus)が挙げられるが、ヒト腸管における高い生存率等の性質を有し、食品に適用した際に生残性が高く、香味、物性も優れているものが好ましい。
LP28株は、リュウガン(果物)から本発明者らによって初めて分離されたものであり、16S rDNAの塩基配列がペディオコッカス・ペントサセウス (Pediococcus pentosaceus) ATCC 25745株のそれ (DDBJ / GenBank / EMBL ID = FM179610) と99.5%の相同性を示し、グラム染色後の顕鏡下において四連球菌の様相を呈することから、ペディオコッカス・ペントサセウス (Pediococcus pentosaceus) と同定された。LP28株の主な菌学的性質を以下に示す。
1)グラム陽性乳酸球菌、2)ホモ型乳酸発酵、3)カタラーゼ陰性、4)芽胞形成能無し、5)好気条件下でも培養可、6)菌体外多糖類を産生。
培養方法は、静置培養又はpHを一定にした中和培養や、回分培養及び連続培養等、菌体が良好に生育する条件であれば、特に制限はない。
また、培養に際しては、酒粕若しくは焼酎蒸留残渣又はそれらの抽出物を添加することが好ましく、特に発酵乳、発酵果汁又は発酵野菜汁を製造する場合には、これらを添加することにより良好な発酵物の製造が可能となり好ましい。
これらの投与形態のうち、好ましい形態は経口投与である。
以下に、実施例及び試験例を示し、本発明についてより詳細に説明する。
MRS培地(メルク社)を118℃で15分間殺菌した後、ペディオコッカス・ペントサセウス(Pediococcus pentosaceus) LP28株(NITE AP-700として、独立行政法人製品評価技術基盤機構特許微生物寄託センターに寄託(2009年1月27日))を接種し、28℃で36時間嫌気培養し、得られた培養物をPBSで3回洗浄後、凍結乾燥してLP28株の菌体粉末を得、実験に用いるまで-80℃において保存した。また、比較として、ソーセージより入手したLactobacillus plantarum SN13T株(NITE P-7)を同様に培養し、SN13T株の菌体粉末を得た。
(1)試験方法
7〜8週齢のマウス(BALB/c)に6週間にわたって高脂肪食(D12492-Rodent Diet with 60 kcal% Fat, Research Diets Inc., New Brunswick, NJ)を摂取させ、肥満を誘発させた後、更に8週間、同高脂肪食のほか、製造例1で調製したLP28株及びSN13T株の菌体粉末を摂取あるいは非摂取させ、体重の変化を観察した。また、菌体摂取開始8週後に、各個体の腹腔内の白色脂肪組織重量および肝中性脂肪量を測定した。
尚、肝中性脂肪量は、肝をクロロホルム/メタノール(2:1)で懸濁、振盪した後、クロロホルム層のトリグリセリド量を定量した(トリグリセライド定量用トリグリセライドE-テストワコー/和光純薬工業)。
また、LP28株及びSN13T株の菌体粉末の摂取は、砕いた餌1gに対し、菌体培養物粉末25mgを混合し、マウス(各群、5匹ずつ)に自由摂取させた。餌の摂取量は、乳酸菌非摂取群、LP28摂取群、SN13T摂取群間で差は見られず、1日当たり約2.5g/mouseであった。
LP28摂取群では、非摂取群と比べ、高脂肪食摂取による体重増加が有意に抑制(P<0.05)されたが、SN13T摂取群では、非摂取群と差は見られなかった(図1)。さらに、高脂肪食摂取時における白色脂肪組織重量(図2)、肝重量及び肝中性脂肪量が減少した(図3)。
このように、LP28には、過栄養状態における体重増加、脂肪増加、および脂肪肝を抑制する効果が認められたことから、メタボリック症候群の予防・改善に有効であると考えられる。
試験例1における被験動物のうち、LP28摂取群と非摂取群の各1匹の肝よりtotal RNAを抽出し、cDNAマイクロアレイ解析(Affymetrix)を実施した。
その結果、超低密度リポタンパク質受容体(Very low density lipoprotein receptor)、CD36抗原(CD36 antigen)、PPARγ(Peroxisome proliferator activated receptor gamma)、ステアリン酸CoA 脱飽和酵素1(Stearoyl-Coenzyme A desaturase 1)、SREBF1(Sterol regulatory element binding transcription factor 1)、脂肪酸シンターゼ(Fatty acid synthase)をはじめとして、多くの脂質関連遺伝子の発現変動が認められた。
ペディオコッカス・ペントサセウス(Pediococcus pentosaceus) LP28株(NITE AP-700)を梨濃縮汁100%還元品、1.0%クエン酸ナトリウム及び1.0%焼酎蒸留残渣抽出物を含む培地にて30℃で20時間培養し、前培養液とした。13%脱脂粉乳(明治乳業社製) に1%焼酎蒸留残渣抽出物を加えたものを121℃で15分殺菌後、30℃まで冷却して本培養培地とし、これに前培養液を2%量接種し、30℃、24時間培養し、発酵乳(乳酸酸度0.59%)を得た。
ペディオコッカス・ペントサセウス(Pediococcus pentosaceus) LP28株(NITE AP-700)を、梨濃縮汁100%還元品、1.0%クエン酸ナトリウム及び1.0%焼酎蒸留残渣抽出物を含む培地にて30℃で20時間培養し、前培養液とした。ニンジン濃縮汁の100%還元品に0.1%脱脂粉乳及び0.8%焼酎蒸留残渣抽出物を加えたものを105℃で5分殺菌後、30℃まで冷却して人参汁培地を作成し、これに前培養液を2%量接種し、30℃、24時間培養し、発酵ニンジン汁(乳酸酸度0.61%)を得た。
Claims (5)
- 独立行政法人製品評価技術基盤機構特許微生物寄託センターに、NITE BP−700として寄託されたペディオコッカス・ペントサセウス(Pediococcus pentosaceus)LP28株の菌体若しくは菌体培養物を有効成分とする肥満予防又は改善剤。
- 独立行政法人製品評価技術基盤機構特許微生物寄託センターに、NITE BP−700として寄託されたペディオコッカス・ペントサセウス(Pediococcus pentosaceus)LP28株の菌体若しくは菌体培養物を有効成分とする脂肪蓄積抑制剤。
- 独立行政法人製品評価技術基盤機構特許微生物寄託センターに、NITE BP−700として寄託されたペディオコッカス・ペントサセウス(Pediococcus pentosaceus)LP28株の菌体若しくは菌体培養物を有効成分とする脂質代謝改善剤。
- 独立行政法人製品評価技術基盤機構特許微生物寄託センターに、NITE BP−700として寄託されたペディオコッカス・ペントサセウス(Pediococcus pentosaceus)LP28株の菌体若しくは菌体培養物を含有する肥満予防又は改善用食品。
- 独立行政法人製品評価技術基盤機構特許微生物寄託センターに、NITE BP−700として寄託されたペディオコッカス・ペントサセウス(Pediococcus pentosaceus)LP28株。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009046388A JP5569710B2 (ja) | 2009-02-27 | 2009-02-27 | 肥満予防又は改善剤 |
US13/203,523 US20110311502A1 (en) | 2009-02-27 | 2010-02-26 | Agent for prevention or amelioration of obesity |
TW099105718A TWI461154B (zh) | 2009-02-27 | 2010-02-26 | Obesity prevention or ameliorating agent |
KR1020117019279A KR101660272B1 (ko) | 2009-02-27 | 2010-02-26 | 비만예방 또는 개선제 |
EP10746014.9A EP2402431B1 (en) | 2009-02-27 | 2010-02-26 | Pediococcus pentosaceus lp28 for use in the prevention or amelioration of obesity |
PCT/JP2010/001334 WO2010098131A1 (ja) | 2009-02-27 | 2010-02-26 | 肥満予防又は改善剤 |
US14/327,893 US9387228B2 (en) | 2009-02-27 | 2014-07-10 | Agent for prevention or amelioration of obesity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009046388A JP5569710B2 (ja) | 2009-02-27 | 2009-02-27 | 肥満予防又は改善剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010200611A JP2010200611A (ja) | 2010-09-16 |
JP5569710B2 true JP5569710B2 (ja) | 2014-08-13 |
Family
ID=42665344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009046388A Active JP5569710B2 (ja) | 2009-02-27 | 2009-02-27 | 肥満予防又は改善剤 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20110311502A1 (ja) |
EP (1) | EP2402431B1 (ja) |
JP (1) | JP5569710B2 (ja) |
KR (1) | KR101660272B1 (ja) |
TW (1) | TWI461154B (ja) |
WO (1) | WO2010098131A1 (ja) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6453534B2 (ja) * | 2012-09-28 | 2019-01-16 | 小林製薬株式会社 | 脂質代謝促進剤 |
US10046017B2 (en) * | 2014-01-09 | 2018-08-14 | Nestec S.A. | Pomegranate skin extract for treating fatty liver |
CN104171429A (zh) * | 2014-08-14 | 2014-12-03 | 生合生物科技股份有限公司 | 一种植物乳杆菌lp28的用途 |
US10792302B2 (en) | 2016-02-24 | 2020-10-06 | Noster Inc. | Composition for preventing or treating metabolism disorders comprising leuconostoc mesenteroides-producing exopolysaccharide as active ingredient |
KR101797926B1 (ko) * | 2016-11-21 | 2017-11-15 | 한국식품연구원 | 포름산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물 |
KR101912774B1 (ko) * | 2016-11-21 | 2018-10-29 | 한국식품연구원 | 포름산 생성능이 우수한 균주를 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물 |
JP6886614B2 (ja) * | 2016-12-13 | 2021-06-16 | 一興 石原 | 大豆を原料とする発酵ゲル |
KR101942079B1 (ko) * | 2017-10-11 | 2019-01-24 | 서울대학교 산학협력단 | 약콩 유산균 발효물을 함유하는 심혈관 질환 예방 및 개선용 조성물 |
JP7008660B2 (ja) * | 2018-03-29 | 2022-01-25 | キッコーマン株式会社 | 液状食品組成物及びその製造方法 |
KR102406639B1 (ko) * | 2019-07-19 | 2022-06-10 | 한국 한의학 연구원 | 페디오코쿠스 이노피나투스를 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물 |
KR102328743B1 (ko) * | 2020-06-12 | 2021-11-22 | 숙명여자대학교산학협력단 | 신규한 페디오코커스 펜토사세우스 균주 및 이의 유청 발효물을 포함하는 비만 또는 지방간 질환의 예방 또는 개선용 식품 조성물 |
CN117143785B (zh) * | 2023-11-01 | 2024-02-27 | 中国农业科学院饲料研究所 | 一株片球菌及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0657657B2 (ja) * | 1987-05-27 | 1994-08-03 | ニチニチ製薬株式会社 | 抗高脂血症剤 |
US4877615A (en) * | 1988-09-23 | 1989-10-31 | Microlife Technics, Inc. | Antifungal product |
PT862863E (pt) | 1997-01-09 | 2002-04-29 | Nestle Sa | Produto cerealifero contendo probioticos |
AUPQ387599A0 (en) * | 1999-11-05 | 1999-12-02 | Metabolic Pharmaceuticals Limited | Product and method for control of obesity |
JP4580542B2 (ja) | 2000-05-17 | 2010-11-17 | 株式會社バイオニア | 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物 |
US20060233777A1 (en) * | 2003-04-01 | 2006-10-19 | Andrea Piva | Use of bacteriocin for the amelioration of digestive functionality |
US20050130288A1 (en) * | 2003-12-11 | 2005-06-16 | Eromlife Co., Ltd. | Novel microorganism Pediococcus pentosaceus EROM101, having immune enhancement, anticancer and antimicrobial activities |
SE0400355D0 (sv) * | 2004-02-17 | 2004-02-17 | Synbiotics Ab | New synbiotec use |
JP5247012B2 (ja) | 2006-07-25 | 2013-07-24 | 雪印メグミルク株式会社 | 脂肪肝抑制剤 |
JP5201832B2 (ja) * | 2006-12-25 | 2013-06-05 | 花王株式会社 | 脂肪分解促進用皮膚外用剤 |
JP2008178398A (ja) * | 2006-12-27 | 2008-08-07 | Hayashikane Sangyo Kk | 動物性タンパク質の乳酸発酵物、その製造方法、ならびにこの乳酸発酵物を含む食品及び健康食品 |
JP2008214253A (ja) | 2007-03-02 | 2008-09-18 | Snow Brand Milk Prod Co Ltd | 内臓脂肪減少剤 |
-
2009
- 2009-02-27 JP JP2009046388A patent/JP5569710B2/ja active Active
-
2010
- 2010-02-26 US US13/203,523 patent/US20110311502A1/en not_active Abandoned
- 2010-02-26 KR KR1020117019279A patent/KR101660272B1/ko active IP Right Grant
- 2010-02-26 EP EP10746014.9A patent/EP2402431B1/en not_active Not-in-force
- 2010-02-26 WO PCT/JP2010/001334 patent/WO2010098131A1/ja active Application Filing
- 2010-02-26 TW TW099105718A patent/TWI461154B/zh not_active IP Right Cessation
-
2014
- 2014-07-10 US US14/327,893 patent/US9387228B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2010200611A (ja) | 2010-09-16 |
US9387228B2 (en) | 2016-07-12 |
EP2402431A1 (en) | 2012-01-04 |
US20140322186A1 (en) | 2014-10-30 |
WO2010098131A1 (ja) | 2010-09-02 |
KR101660272B1 (ko) | 2016-09-27 |
TWI461154B (zh) | 2014-11-21 |
EP2402431A4 (en) | 2013-04-03 |
KR20110121688A (ko) | 2011-11-08 |
EP2402431B1 (en) | 2015-05-27 |
US20110311502A1 (en) | 2011-12-22 |
TW201043151A (en) | 2010-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5569710B2 (ja) | 肥満予防又は改善剤 | |
US9750775B2 (en) | Lactic acid bacterium-containing preparation | |
JP4834798B2 (ja) | 新規ビフィズス菌、耐糖能改善剤、および抗肥満剤 | |
AU2008222007B2 (en) | Agent for reducing visceral fat | |
Liu et al. | The probiotic role of Lactobacillus plantarum in reducing risks associated with cardiovascular disease | |
WO2005092122A1 (ja) | ユッカ抽出物、キラヤ抽出物及び乳酸菌からなる組成物及び同組成物を含有する飲食品 | |
WO2015146916A1 (ja) | 新規ラクトバチラス・パラカゼイ株 | |
US10022407B2 (en) | Use of a lactobacillus rhamnosus strain for reducing weight gain and/or insulin resistance | |
KR102543494B1 (ko) | 신규 프로바이오틱스 및 이의 용도 | |
Kurpad | Potential of probiotics in hypercholesterolemia: a review of in vitro and in vivo findings | |
US11484557B2 (en) | Human-derived Lactobacillus fermentum MG4231 or Lactobacillus fermentum MG4244 strain having anti-obesity activity, and composition comprising same | |
KR102037108B1 (ko) | 케피어 유래 유산균 또는 효모의 사균체를 함유하는 비만의 예방 또는 치료용 조성물 | |
JP2007126399A (ja) | グルタチオン増加用組成物 | |
JPWO2018174125A1 (ja) | 脂質代謝改善用組成物 | |
TW202207957A (zh) | 具有優異的耐酸性和耐膽汁性且對血脂異常症具有預防或治療效果的新型短雙歧桿菌idcc 4401菌株及其死菌體id-bbr4401 | |
Sharma et al. | The Title Page | |
WO2011025019A1 (ja) | チオレドキシン誘導活性を有する乳酸菌ならびにチオレドキシンを介する生体傷害の予防および/または改善用の飲食品および医薬品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131216 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140603 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140611 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5569710 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |